DM177533

From: Research Station Genesis To: Director, Research Facility, Project Abraham Re: Summary of Results of Serum Injection in Subject JAS Date: 12/4/1949

Preliminary tests indicated that serum run 51 should, in the short run, provide a healthy test subject with immunity to the virus and should ward off transformation. But in a trial with subject JAS, test subject showed little immunity and major transformation.

Subject JAS initially showed a response comparable to previous test subjects (standard progression based on Russian trials, provided by Malikov.) The expectation was that with the current serum, viral load (as measured in RNA copies per ml, see exhibit 1) would fell to undetectable levels, and that JAS would not transform.

JAS showed an uncharacteristic in viral load at about week 8, and physical changes continued as well.

Subsequent testing has revealed subject JAS had an asymptomatic viral infection (mononucleosis) which took up residence in B-lymphocyte cells. Asymptomatic infection is probably common in a small percentage of apparently healthy Americans. However, the resulting mild compromise of the immune system meant that the serum virus was not well checked by normal immunological function.

The viral load for JAS is now at unacceptably high levels. Transformation, while nonstandard, is irreversible.